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to identify investments required to establish a national breast cancer program 
across KSA.
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Objectives: To assess co-relation of GDP per capita (purchasing power parity) on 
pharmaceutical pricing. MethOds: Based on empirical research, 18 drugs were 
selected and grouped into seven therapeutic categories: (1) Blood Based Disorders; (2) 
Cardiovascular Disorders; (3) Inflammatory Disorders; (4) Oncology; (5) Respiratory 
Disorders (only fluticasone); (6) Diabetes; and (7) Viral Diseases Price per unit (mg, IU, 
and U; at ex-factory level) data was collected from IHS PharmOnline International 
(POLI) Database across 41 countries (Australia, Austria, Belgium, Brazil, Bulgaria, 
Canada, China, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, India, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, 
Morocco, The Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, 
Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Turkey, UK, and United 
States) from 2007 to 2012. Prices were converted into Euros on a yearly exchange 
rate basis and adjusted for inflation. Additionally, GDP data was collected from 
World Bank for the same period. We fit the regression equation for the log price per 
unit (dependent variable), log GDP per capita, generic status, strength, percentage 
of population aged 65 and above, an indicator for the US market, and year (inde-
pendent variables) as follows: Y (Price per Unit) = α + ∑ β i * Xi + ε . Results: eltrom-
bopag (-0.977+.131, n= 160), filgrastim (-4.08+. 347, n= 1420), etanercept (-.253+. 227, 
n= 870), adalimumab (2.52+. 128, n= 306), cetuximab (-.325+.166, n= 203), pazopanib 
(-3.78+.164, n= 111), fluticasone (.559+.559, n= 108), sitagliptin (-4.00+.215, n= 413), 
Stocrin (-12.75+.803, n= 556) and Truvada (-5.08+.157, n= 168) had statistically sig-
nificant GDP (PPP) coefficients at the 0.01 level, whereas Tasigna, bevacizumab, 
dabigatran, rivaroxaban, exenatide, liraglutide, saxagliptin, and interferon alpha 
were not significant at 0.01 level. cOnclusiOns: Our model finds varying degrees 
of co-relation between GDP per capita (PPP) and price per unit. Nonetheless, sitag-
liptin, cetuximab, filgrastim, Stocrin, Truvada, and adalimumab exhibited highest 
co-relation; they are thus most differentially priced.
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Objectives: Chemotherapy-induced FN is associated with increased morbid-
ity and mortality and frequently leads to hospitalization. This analysis aimed to 
describe FN-HCRU in patients hospitalized for FN in Bulgaria. MethOds: Eleven 
Bulgarian centres contributed to this international, retrospective, observational 
study conducted in Bulgaria, Czech Republic, and Slovakia. Adult patients with ST 
or HM receiving the chemotherapy leading to the first (= index) FN event between 
01/2009 and 09/2012 and at least one confirmed FN event were enrolled. FN-specific 
HCRU parameters included infection prophylaxis and treatments, G-CSF use, other 
prophylactic medication, specific interventions and investigations, and FN-related 
hospitalizations. Results: 156 Bulgarian patients were analysed (ST= 64, HM= 92); 
median age: 55.5 years, ECOG 0-2: 81%. All of ST and 79% of HM had one FN episode 
(≥ 3 episodes: 6%) with a mean (SD) number of FN-related hospital days of 6.6 (4.75) 
and 7.7 (4.79). Chemotherapy was completed as planned in 38% of ST and 87% of HM 
patients. In the index cycle, G-CSF was predominantly administered as treatment 
(86%, 48%), with a minority used as primary prophylaxis in ST (5%) and HM (30%) 
patients. In the index cycle, FN-related investigations were conducted in 83% of ST 
patients (207 investigations) and 78% of HM patients (324 investigations), mostly 
blood tests (ST= 83%, HM= 68%) or imaging (ST= 14%, HM= 20%). FN-related interven-
tions were conducted in 70% each of ST (220 interventions) and HM patients (196 
interventions), mainly IV fluids (ST= 64%, HM= 56%) or blood transfusions (ST= 17%, 
HM= 27%). In ST, 6 of 7 (86%), in HM 2 of 10 (20%) deaths during the observational 
period were FN-related. cOnclusiOns: The data showed considerable HCRU in 
patients experiencing FN in Bulgaria, with frequent lack of G-CSF prophylaxis 
observed, particularly in ST patients. Improved G-CSF targeting may reduce FN 
and lower associated HCRU.
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Objectives: To examine patient characteristics, health care resource utiliza-
tion (HRU) and medical costs of patients who were untreated for neuroendocrine 
tumors (NETs). MethOds: Using a US administrative claims database, commer-
cially-insured adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209. xx) 
or pancreatic islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 
12/31/2010 were identified (the first observed diagnosis date as the index date). 
Patients were required to have 6-month pre-index and 12-month post-index enroll-
ment. Untreated patients were defined as those receiving neither surgical nor 
medical treatments in the 12-month follow-up period. Descriptive analysis was 
Objectives: NAT for eBC have potential benefits in reducing tumor size, permit-
ting breast conservation, identifying effective adjuvant regimens, and providing 
prognostic information. This study investigated the characteristics of eBC patients, 
real-world utilization patterns of NAT, and health care costs from diagnosis to 
primary surgery (neoadjuvant phase) using a US claims database. MethOds: A 
cohort from the IMS PharMetrics Plus database included female patients, aged 
18+, with the first (index) breast cancer (BC) diagnosis (ICD-9-CM 174. x, 233.0) 
between July 2006 and September 2012, primary surgery (mastectomy or lumpec-
tomy) after index, continuous enrollment from 180 days before index (pre-index) 
to 90 days after surgery, no pre-index diagnosis for BC or other primary cancer, 
and no secondary malignancy from pre-index to surgery. Systemic therapies used 
by this cohort in neoadjuvant phase were assumed as NAT. Patients with eBC 
trastuzumab use were presumed HER2+. Results: Of 57,032 eligible eBC patients 
(median age= 56), 2,011 (3.5%) received NAT. Patients who received NAT had pri-
mary surgery in a median of 166 days after index diagnosis vs. 21 days for patients 
who did not receive NAT. Among patients receiving NAT, 485 (24.1%) had trastu-
zumab, with TCH (docetaxel, carboplatin, trastuzumab) and ACTH (doxorubicin, 
cyclophosphamide, a taxane, trastuzumab) most frequently used (49.5% and 
26.2%, respectively). FEC regimen (5-flurouracil, epirubicin, cyclophosphamide) 
was used by only 5.6% trastuzumab users. From 2007 to 2011, there was a 46% 
increase in proportion of trastuzumab use in NAT users (19.6% to 28.6%). Among 
eBC patients receiving NAT, trastuzumab users had a higher monthly health care 
cost in neoadjuvant phase ($17,425 vs. $11,422) than those without trastuzumab 
use; however, the out-of-pocket spending by patients ($389 vs. $370) was simi-
lar. cOnclusiOns: Based on these real-world data, neoadjuvant use of systemic 
therapies was infrequent. Among the patients with HER2+ eBC, TCH and ACTH 
were the most frequently used neoadjuvant regimens, consistent with their use 
in the adjuvant setting.
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Objectives: The use of off-label medication is restricted by government in some 
countries, because using off-label anticancer drugs has some concerns about its 
efficacy and toxicity. HIRA (Health Insurance Review & Assessment Service) has the 
process for the assessment and control for the off-label use of anticancer drugs in 
South Korea. We would introduce the controlling for the off-label use of anticancer 
drugs and evaluate the trend of off-label use in anticancer drugs. MethOds: Since 
Dec. 2006, HIRA has permitted off-label uses for which there is adequate evidence 
for the efficacy, toxicity, and cost effectiveness. We collected the patient’s medi-
cal record data (briefly recorded response rate, major adverse effects. etc) which 
updated every year from hospital. We defined 37 cancers (36 cancers, other cancer) 
and preparative regimens of Hematopoietic stem cell transplantation. We calculated 
the number of approved off-label regimens by year and cancer type, and the regimen 
of the most widely used. Results: From Dec. 2006 to 2013, total 203 off-label regi-
mens were approved their use in 63 hospitals (number of cumulative cases: 16,596). 
From 2006 to 2012, the number of approved off-label regimen was increased (1, 3, 
3, 14, 39.37, 67, respectively). In 2013, only 38 regimens were approved. Compared 
with the other cancer, non-Hodgkin lymphoma (30 regimens, 15%), ovarian cancer 
(10 regimens, 5%), and CLL (10 regimens, 5%) have many off-label regimens. The 
regimens: “< 3 weekly> S-1 + cisplatin for gastric cancer” was the most widely used 
regimens (59 hospitals, number of cumulative cases: 2,283). cOnclusiOns: The use 
of off-label anticancer drugs has been increased in South Korea since 2006. These 
results suggest that the development of new drugs and the more clinical trials 
should be needed in cancer disease.
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Objectives: To develop a national breast cancer (BC) screening program through 
phased regional expansion using an advanced investment decision support 
simulation model informed by real world data in the Kingdom of Saudi Arabia 
(KSA). MethOds: An agent-based modeling simulation (ABMS) tool will represent 
the KSA female population, BC burden and existing health system and project 
impact of infrastructure investment options. Data are drawn from existing sources 
including census, registries and health surveys; phased studies will generate real 
world data on the outcomes of new clinical interventions. In Phase 1, a mobile BC 
screening program was deployed in Riyadh with three mobile clinics equipped 
with appropriate technology and medical staffing with the goal to screen at least 
10,000 women during 2012-2014 and establish a care pathway for accurate diag-
nosis. The modeling and phased studies will guide the national program develop-
ment by evaluating the impact of investments on BC screening rates, outcomes 
and economic value. Results: The Phase 1 Riyadh program screened 12,877 
females and established a care pathway model leading to 83 confirmed BC diagno-
ses (rate: 6.4 per 1000). Data visualization plotting breast cancer disease prevalence 
and mammogram installed base identified areas of high need and low resources in 
the regions of Riyadh, Hafr Al-Baten, Eastern, Al-Ahsa and Al-Jouf. The ABMS model 
to be developed will evaluate the impact of investment scenarios encompassing 
expansion of existing facilities and manpower, development of new radiology 
centers, and implementation of additional mobile programs. cOnclusiOns: 
The Riyadh program revealed higher rate of breast cancer in the region than pre-
viously reported, emphasizing the need to ensure access for accurate diagnosis 
and create a national program. Data visualization readily identified regions for 
prioritized expansion. Real world data will continue to inform the ABMS model 
